公开(公告)号：WO2016097313A1

公开(公告)日：2016-06-23

申请号：PCT/EP2015/080536

申请日：2015-12-18

Applicant: ABLYNX N.V.

Inventor： JANSSEN, Daniel ,  SCHOTTE, Peter ,  DESCAMPS, Francis ,  BOUTTON, Carlo ,  CASTEELS, Peter

IPC: C07K16/18 ,  C07K16/28

CPC classification number: A61K47/6879 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6843 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1045 ,  A61K51/1051 ,  A61K51/109 ,  A61K51/1096 ,  A61K2039/505 ,  C07K1/16 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

Abstract translation: 本发明涉及包含第一多肽和第二多肽的二聚体，其中所述第一和第二多肽中的每一个包含至少一个免疫球蛋白单可变结构域（1ISVD）和包含半胱氨酸部分的C-末端延伸（优选在C- 末端），其中所述第一多肽和所述第二多肽通过所述第一多肽的半胱氨酸部分和所述第二多肽的半胱氨酸部分之间的二硫键共价连接，其中二聚体优于基准构建体，例如 在多种测定中，同源多价和多特异性构建体。 本发明提供了制备本发明的二聚体的方法。

公开(公告)号：WO1997016221A2

公开(公告)日：1997-05-09

申请号：PCT/IB1996001277

申请日：1996-10-30

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： THE UAB RESEARCH FOUNDATION ,  BUCHSBAUM, Donald, J. ,  RABEN, David ,  KHAZAELI, Mohammad, B. ,  STACKHOUSE, Murray ,  CURIEL, David

IPC: A61N00/00

CPC classification number: A61K51/1036 ,  A61K38/00 ,  A61K38/105 ,  A61K38/1796 ,  A61K48/00 ,  A61K51/08 ,  A61K51/088 ,  A61K51/10 ,  A61K2123/00 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/3007 ,  C07K2317/77

Abstract: The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing said tumor with a gene encoding a membrane expressed protein unique to said tumor; and administering to said individual a radiolabeled ligand which specifically binds to said protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.

Abstract translation: 本发明提供了一种在肿瘤部位实现放射性同位素定位的方法，即在需要这种治疗的个体中增强放射性标记的配体定位于肿瘤的方法，包括以下步骤：用编码膜表达的基因转导所述肿瘤 所述肿瘤独特的蛋白质; 并向所述个体施用特异性结合所述蛋白质的放射性标记的配体。 使用基因治疗技术诱导高亲和力膜分子/受体的表达可以增强放射性同位素定位的特异性，而使用具有在几个细胞直径上传递辐射损伤的能力的放射性同位素将补偿不到完美的转导效率。

公开(公告)号：US20170107292A1

公开(公告)日：2017-04-20

申请号：US15291597

申请日：2016-10-12

Applicant: Woomera Therapeutics, Inc

Inventor： William G. North ,  Roy H.L. Pang

IPC: C07K16/28 ,  A61K45/06 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2869 ,  A61K38/00 ,  A61K38/31 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0058 ,  A61K51/1036 ,  A61K51/1063 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  C07K7/06 ,  C07K14/4703 ,  C07K14/72 ,  C07K16/26 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92 ,  G01N33/57492 ,  A61K2300/00

Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

公开(公告)号：US20140341810A1

公开(公告)日：2014-11-20

申请号：US14274999

申请日：2014-05-12

Applicant: William G. North ,  Roy H.L. Pang

Inventor： William G. North ,  Roy H.L. Pang

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/574 ,  C07K14/72 ,  C07K7/06 ,  A61K39/395 ,  A61K49/00

CPC classification number: C07K16/2869 ,  A61K38/00 ,  A61K38/31 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0058 ,  A61K51/1036 ,  A61K51/1063 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  C07K7/06 ,  C07K14/4703 ,  C07K14/72 ,  C07K16/26 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92 ,  G01N33/57492 ,  A61K2300/00

Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

Abstract translation: 本文提供了异常加压素受体V2（例如，AbnV2）的拮抗剂或结合剂，例如抗体和针对受体特异性的抗原结合部分，用于鉴定和靶向表达这种异常加压素受体V2的癌细胞。 另外提供了使用所述拮抗剂或结合剂的方法，例如在体内和体外成像癌细胞或生物样品或诊断癌症。 拮抗剂或结合剂也可用于治疗患有表达异常升压素受体V2的癌症患者，如小细胞肺癌（SCLC），乳腺癌或卵巢癌。

公开(公告)号：US20110117105A1

公开(公告)日：2011-05-19

申请号：US12987814

申请日：2011-01-10

Applicant: Milton David GOLDENBERG

Inventor： Milton David GOLDENBERG

IPC: A61K39/395 ,  A61P37/02

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：US20060067885A1

公开(公告)日：2006-03-30

申请号：US11229872

申请日：2005-09-20

Applicant: David Goldenberg

Inventor： David Goldenberg

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

公开(公告)号：US06331175B1

公开(公告)日：2001-12-18

申请号：US09110181

申请日：1998-07-06

Applicant: Milton David Goldenberg

Inventor： Milton David Goldenberg

IPC: A61M2500

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to above-mentioned tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供进入上述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向的器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：US5902583A

公开(公告)日：1999-05-11

申请号：US739826

申请日：1997-02-11

Applicant: Donald J. Buchsbaum ,  David T. Curiel ,  Mohammad B. Khazaell ,  David Raben ,  Murray Stackhouse

Inventor： Donald J. Buchsbaum ,  David T. Curiel ,  Mohammad B. Khazaell ,  David Raben ,  Murray Stackhouse

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/135 ,  A61K31/138 ,  A61K31/22 ,  A61K31/223 ,  A61K35/76 ,  A61K38/00 ,  A61K38/04 ,  A61K38/17 ,  A61K38/22 ,  A61K39/395 ,  A61K48/00 ,  A61K51/00 ,  A61K51/08 ,  A61K51/10 ,  A61M36/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/82 ,  C07K16/30 ,  A01N43/04

CPC classification number: A61K51/1036 ,  A61K38/105 ,  A61K38/1796 ,  A61K51/08 ,  A61K51/088 ,  A61K51/10 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/3007 ,  A61K2123/00 ,  A61K38/00 ,  A61K48/00 ,  C07K2317/77

Abstract: The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing the tumor with a gene encoding a membrane expressed protein unique to the tumor; and administering to said individual a radiolabeled ligand which specifically binds to the protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.

Abstract translation: 本发明提供了一种在肿瘤部位实现放射性同位素定位的方法，即一种增强放射性标记的配体定位于需要这种治疗的个体中的肿瘤的方法，包括以下步骤：用编码膜表达的基因转导肿瘤 蛋白质独特的肿瘤; 并向所述个体施用特异性结合蛋白质的放射性标记的配体。 使用基因治疗技术诱导高亲和力膜分子/受体的表达可以增强放射性同位素定位的特异性，而使用具有在几个细胞直径上传递辐射损伤的能力的放射性同位素将补偿不到完美的转导效率。

公开(公告)号：US5697902A

公开(公告)日：1997-12-16

申请号：US456909

申请日：1995-06-01

Applicant: Milton David Goldenberg

Inventor： Milton David Goldenberg

IPC: A61K49/00 ,  A61B5/05 ,  A61B5/055 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K49/16 ,  A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  A61P35/00 ,  A61P43/00 ,  C07K20060101 ,  C07K16/18 ,  C07K16/28 ,  C07K17/00 ,  G01N33/53 ,  G01R33/28 ,  G01R33/48 ,  A61M31/00

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  B82Y5/00 ,  A61K2123/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：WO2013071038A3

公开(公告)日：2013-08-08

申请号：PCT/US2012064348

申请日：2012-11-09

Applicant: WOOMERA THERAPEUTICS

Inventor： NORTH WILLIAM G ,  PANG ROY H L

IPC: A61K38/08 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2869 ,  A61K38/00 ,  A61K38/31 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0058 ,  A61K51/1036 ,  A61K51/1063 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  C07K7/06 ,  C07K14/4703 ,  C07K14/72 ,  C07K16/26 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92 ,  G01N33/57492 ,  A61K2300/00

Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

Abstract translation: 本文提供的是异常加压素受体V2（例如，AbnV2）的拮抗剂或结合剂，例如抗体和针对受体特异性的抗原结合部分，用于鉴定和靶向表达这种异常加压素受体V2的癌细胞。 另外提供了使用所述拮抗剂或结合剂的方法，例如在体内和体外成像癌细胞或生物样品或诊断癌症。 拮抗剂或结合剂也可用于治疗患有表达异常加压素受体V2的癌症患者，例如小细胞肺癌（SCLC），乳腺癌或卵巢癌。